Abilita Therapeutics is a biotechnology company advancing the discovery and development of novel drugs targeting membrane proteins linked to cancer, obesity, pain, and inflammatory diseases. Its proprietary platform generates stable, whole-protein antigens—unlocking new possibilities for therapies that were previously out of reach.
Arch Systems is an AI co-pilot for manufacturing delivering factory intelligence that acts like a seasoned expert. It closes the loop from real-time data to prescriptive action without extra dashboards or staff. Arch helps factories run faster and cheaper, turning wasted hours into profit for manufacturers.
Binarly is an AI-powered cybersecurity company that protects against the number one threat to companies today: an attack on their software supply chain. Its platform detects vulnerabilities, misconfigurations, exposed secrets, and malicious code before they put a company at risk. It is the only technology that can analyze compiled software without accessing its source code and identify the sophisticated, unknown threats that existing security tools are blind to.
CIQ is building the next-generation secure, high-performance software infrastructure stack for the AI era. It helps organizations simplify, unify, and democratize computing and enterprise IT. As the founding support and services partner of Rocky Linux—and the creator of products like Fuzzball, Ascender, and Rocky Linux from CIQ— it delivers scalable, open infrastructure solutions that power innovation from the operating system up.
Conceal delivers a Browser-Native Security Service Edge (SSE) platform that provides Zero Trust Access and in-browser security without relying on VPNs, proxies, or datacenter-routed traffic. It enables secure, direct access to any corporate information system from any device, helping organizations reduce complexity, cost, and risk.
Dymium manages, regulates and protects enterprise data -- providing a way to govern and monitor data access in real-time directly at the source. This ensures that users, applications, and AI agents receive precisely the data they need without the inherent risks of creating insecure copies, positioning Dymium as the essential security layer for the modern data stack.
Elisity is an AI-driven network security company that alleviates cyber threats by wrapping a virtual shield around every user and device, granting access based on identity, not just network location. Their platform monitors and controls how people and devices interact within a network. Elisity is simple to deploy and manage and requires no additional hardware, which makes it a security solution for every organization.
FYR Bio has combined artificial intelligence/machine learning with chemistry and technology advancements to create the next generation of liquid biopsy. This will be transformative in early disease detection but will also provide powerful tools for therapy selection and monitoring, both for patients and for pharma companies, improving the drug development process.
Graphiant is a Network-as-a-Service Data Company delivering a unified network solution for AI, Cloud, SaaS, B2B, and Branch connectivity. Focused on data services, privacy, and sovereign networking, Graphiant provides end-to-end visibility, control, and compliance. It empowers organizations with real-time insight into network traffic, enabling proactive monitoring, and secure management. With AI reshaping global infrastructure, Graphiant's technology is purpose-built for this next era, addressing gaps the current internet cannot yet meet.
Gravwell is a next-generation enterprise software player with modern, AI-driven capabilities. It is a full-stack data analytics and security platform purpose-built for high-volume, high-fidelity machine data. By enabling organizations to ingest, index, and query logs, network traffic, and event streams at scale, Gravwell empowers security teams to rapidly investigate threats, detect anomalies, and meet compliance requirements without data silos or sampling.
Inimmune has developed novel immunotherapeutics which are in active clinical trials. By harnessing the power of the body's own immune system, Inimmune is developing breakthrough therapies for allergies, cancer, infectious diseases, and autoimmune disorders.
Leapfrog Bio is working to help the 10 million people each year whose cancers come from genetic mutations that current treatments can't fix. Their platform helps find existing drugs that could be reused to treat these cancers but may have failed in clinical trials because they were not targeted specifically at the patients who would benefit from them. By identifying medicines that already exist, the company can move faster and spend less to bring new cancer treatments to patients.
Montara Therapeutics' BrainOnly™ platform is working to make drugs more effective in neurological diseases, while also making them safer. They are developing proprietary combinations: a drug that crosses the brain blood barrier to treat the disease, while a universal peripheral blocker molecule prevents that drug from causing toxic side effects in the rest of the body. This unlocks undruggable targets in CNS diseases and takes advantage of many promising programs stopped due to toxicity.
Novoron Bioscience is biotechnology company pioneering a novel approach to halt neurodegenerative diseases like Alzheimer's. Novoron's value proposition is built upon its proprietary structural insights into the specific interface where pathogenic tau binds to LRP1. It is developing a new class of small molecules that selectively block the disease-causing interaction while preserving the receptor's vital physiological functions.
Numenor AI is an AI company focuses on helping manufacturing companies resolve quality problems before the products leave the factory floor. They are doing this through creating automation around engineering change orders, or ECOs, which govern how changes are made in the manufacturing process. Given the complexity of modern products, resolving this issue has been historically difficult, and their rapid, effective, and traceable resolution can have massive positive impact on business.
Using cutting-edge machine learning and AI models, PulseData enables early intervention, equipping healthcare teams with informed, data-driven insights precisely when they matter most – at the point of care. Mining massive amounts of data, PulseData's patented AI predicts costly medical events before they happen. These proactive models deliver a significant ROI to its partners by saving millions in hospital costs while measurably improving patient health.
QuSecure provides cryptographic agility, allowing organizations to seamlessly transition to quantum-resistant encryption methods without overhauling existing infrastructure. Safeguarding data against the evolving landscape of quantum threats, QuSecure's software solves this by layering quantum-resilient protection over any existing system, making it the fastest and simplest path to becoming secure. The urgency surrounding post-quantum readiness is rapidly escalating, driven by aggressive mandates from the US government.
Rainfall Health is an AI-driven compliance and reimbursement platform that helps hospitals and medical groups navigate new value-based care models such as CMS's TEAM model, ensuring they deliver on vital case management and care delivery goals. The company is shaping a new national standard for mandated care-model compliance through the RAIN Compliant™ designation.
Revenium provides a finance-first solution for AI and API cost governance. Revenium's core offering focuses on converting usage events into auditable invoices or internal charge-backs, providing companies with a way to manage escalating AI costs. By transforming AI from an opaque cost center into a scalable, governable engine for growth, Revenium is positioned to lead a market where previous FinOps pioneers commanded billion-dollar exits.
Sanavia Oncology is a biotechnology company developing new treatments to help the many cancer patients who don't respond to existing therapies. Sanavia uses advanced technologies, including high-throughput sequencing, super-resolution microscopy, computational biology, and artificial intelligence/machine learning to identify unique markers on drug-resistant tumors. Its proprietary platform enables it to replicate cancer biology with unprecedented accuracy, revealing new therapeutic targets at scale.
Selector is an AIOps solution that gives companies complete visibility and intelligence into their highly complex networks, infrastructure, and applications. Selector's AI engine interfaces directly with its industry-first network large language model (NLM) to autonomously sort through enormous volumes of data, making troubleshooting instantaneous. Network teams can have real-time conversations in human language with all their data across warehouses and tooling, fixing issues exponentially faster.
Talus is an AI drug discovery company combining AI, proteomics, synthetic chemistry, and computational biology to create new medicines. Talus's proprietary wet-lab platform can generate data about the control system of the genome at unprecedented scale, allowing them to rapidly optimize new drugs in areas like Oncology, Autoimmunity, Cardiometabolic, Neuro, and Rare Disease.
TileDB allows data scientists to collaborate and make discoveries faster. Unlike traditional cloud database management solutions, TileDB masters the complexity of multimodal data such as genomics, proteomics, single-cell and bioimaging using multi-dimensional arrays. Users organize, structure, collaborate and analyze all in one place, using all their omnimodal, multiomics data to accelerate life sciences breakthroughs.